CollPlant Biotechnologies (CLGN) Common Equity (2017 - 2025)

CollPlant Biotechnologies has reported Common Equity for 9 years, with the latest figure at $6.1 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 54.84% year-over-year to $6.1 million; the trailing twelve-month figure through Dec 2025 stood at $6.1 million (down 54.84% YoY), and the FY2025 full-year result was $6.1 million, down 54.84% from the prior year.
• Common Equity for Q4 2025 stood at $6.1 million, down from $13.5 million in the prior quarter.
• The five-year high for Common Equity was $45.1 million in Q4 2021, with the low at $6.1 million in Q4 2025.
• Historically, Common Equity has averaged $25.1 million across 5 years, with a median of $28.3 million in 2023.
• Annual changes were most pronounced in 2021 — Common Equity soared 907.84% — and 2025, when it sank 54.84%.
• CollPlant Biotechnologies' Common Equity stood at $45.1 million in 2021, then declined by 28.46% to $32.3 million in 2022, then slipped by 12.21% to $28.3 million in 2023, then sank by 52.49% to $13.5 million in 2024, then sank by 54.84% to $6.1 million in 2025.
• The last three Common Equity figures came in at $6.1 million (Q4 2025), $13.5 million (Q4 2024), and $28.3 million (Q4 2023), per Business Quant data.